Agree. There is a mega-trend perspective. There are so many advantages of the DCVax tech platform that just call out as should be competitive in the future to be SOC or at least a base layer SOC treatment (in a combination drug therapy) for all solid tumor cancers. On valuation and market cap, the conversation will have to factor in the potential for and how much of a "winner takes all" effect will there be.
Market Data 
Markets 
AI
